In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., ...
The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback